90Y-ibritumomab Tiuxetan Consolidation After 6th R-CHOP Chemotherapy in Patients With Bulky Diffuse Large B Cell Lymphoma
Phase II Study of 90Y-ibritumomab Tiuxetan Treatment as a Consolidation After 6th R-CHOP Chemotherapy in Patients With Limited-stage, Bulky Diffuse Large B Cell Lymphoma
Sponsor: Asan Medical Center
This PHASE2 trial investigates Lymphoma, Large B-Cell, Diffuse and is currently completed. Asan Medical Center leads this study, which shows 6 recorded versions since 2007 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Jan 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Asan Medical Center
- Chonbuk National University Hospital
- Chonnam National University Hospital
- Dong-A University Hospital
- Pusan National University Hospital
- Samsung Medical Center
- Severance Hospital
For direct contact, visit the study record on ClinicalTrials.gov .